Navigation Links
NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
Date:9/3/2009

EMERYVILLE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY,http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Healthcare Conference at 10 a.m., Thursday, Sept. 10, 2009 at the New York Palace Hotel in New York City.

This presentation will also be made available via webcast athttp://www.wsw.com/webcast/rrshq15/.

Dr. Najafi will provide a corporate overview and highlight NovaBay's clinical progress, business development strategy and product development candidates. His presentation will:

  • Update investors on NovaBay's internal clinical programs in hospital-associated infections and respiratory infections.
  • Provide information on NovaBay's recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay's lead Aganocide((R)) compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE: ACL).
  • Review the partnership with Galderma, the world's leading dermatology company, for development of acne and impetigo products.
  • Discuss the collaborative agreements with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical Univer
    '/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
6. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
7. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
8. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
9. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
10. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
11. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, ... data on the relationship of genetics and hypertension at the International Academy ... in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Calif., May 18, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... Officer of BioMarin, will present a company update at the ... 25, 2011 at 9:30 a.m. GMT.   Interested ... call via the investor section of the BioMarin website, ...
... Northwest Biotherapeutics (OTC Bulletin Board: NWBO ) ... production of DCVax®-L for brain cancer, for clinical trials ... largest applied research foundation in Europe, with a staff ... others dedicated to practical applications and commercialization of research ...
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
Cached Biology Technology:BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference 2Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 2Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 3Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... press release is available in German . ... discovered an unusual regulation of enzymes that catalyze chain ... In the horseradish leaf beetle Phaedon cochleariae ... completely different substances depending on whether it is regulated ...
... OH, February 28, 2013 -- Although the long-term consequences ... have reduced physical education classes to devote more time ... However, there is new evidence that leaving out ... test scores. A new study scheduled for publication ...
... the March issue of GSA Today , seven scientists ... of Leicester, propose a realignment of the terms "geochronology" and ... units of the Geological Time Scale should have a single ... system, which retains both parallel sets of units, with an ...
Cached Biology News:Metal ions regulate terpenoid metabolism in insects 2Metal ions regulate terpenoid metabolism in insects 3Reading, writing, arithmetic, and aerobics -- Evaluating the new 'R' in academic performance 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: